Alkermes saw the highest growth of 1.59% in patent filings in May and 0.99% in grants in June in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.62% and grants by 0.55%. GlobalData’s DataBook provides a comprehensive analysis of Alkermes’s patent filings and grants. Buy the databook here.
Alkermes has been focused on protecting inventions in United States(US) with 13 publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 47% filings and 46% grants. The United States(US), Japan(JP), European Patent Office(EPO), and Hungary(HU) patent Office are among the top ten patent offices where Alkermes is filings its patents. Among the top granted patent authorities, Alkermes has 46% of its grants in United States(US) and 15% in Spain(ES).
Roche and Johnson & Johnson could be the strongest competitors for Alkermes
Patents related to rare diseases and immuno-oncology lead Alkermes's portfolio
Alkermes has the highest number of patents in rare diseases followed by, immuno-oncology. For rare diseases, nearly 100% of patents were filed and 83% of patents were granted in Q2 2024.
Narcolepsy related patents lead Alkermes portfolio followed by cataplexy, and schizophrenia
Alkermes has highest number of patents in narcolepsy followed by cataplexy, schizophrenia, bipolar disorder (manic depression), and depression. For narcolepsy, nearly 29% of patents were filed and 1% of patents were granted in Q2 2024.
For comprehensive analysis of Alkermes's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.